Teva Pharmaceutical Industries Ltd and Mylan NV have shown preliminary interest in a Brazilian generic drugmaking joint-venture in which Pfizer Inc has a 40 percent stake, two people familiar with the process said.
India’s Sun Pharmaceutical Industries Ltd and three buyout firms are also eyeing the venture, Laboratório Teut|Pfizer, said the people, who asked for anonymity since the process is in early stages. Brazil’s Melo family owns the remaining 60 percent of Teuto|Pfizer, Latin America’s largest pharmaceutical plant.
After agreeing to exit Teuto|Pfizer two months ago, the Melos and Pfizer hired the investment-banking units of Goldman Sachs Group Inc and Grupo BTG Pactual SA to oversee the plan, the people said. There is not yet a deadline for submitting proposals for Teuto|Pfizer, the people said.
Teuto|Pfizer, in the centerwest Brazilian city of Anápolis, declined to comment, as did Pfizer. In an email to Reuters, Israeli generic drugs maker Teva said it would not comment on market rumors. Sun Pharmaceutical, UK-headquartered Mylan, Goldman Sachs and BTG Pactual did not have an immediate comment.
The sale underscores the challenge facing generic drugmakers in Brazil, where a weaker currency has stoked raw materials costs and the harshest recession in eight decades has slowed sales. Pfizer will decide this year whether to globally exit generic drugs, after plans to buy rival Allergan Inc collapsed.
Generic drug sales in Brazil, Latin America’s largest economy, expanded 10 percent last year, slowing from 15 percent growth in 2014, industry data showed. Revenue from sales of generic drugs in Brazil topped 46 billion reais ($14 billion) last year.
OPTION
The people declined to detail the price the Melos and Pfizer, the biggest U.S. drugmaker, want for Teuto. Pfizer paid $240 million for the Teuto stake six years ago, to enter Brazil’s then-buoyant generic drug market.
At the time, Walderci de Melo, who bought Teuto in 1986 with his brother Lucimar, negotiated terms of an option that gave Pfizer the right to acquire the remainder of Teuto|Pfizer at 14.4 times operational profit between 2014 and 2016, one of the people said.
However, Pfizer’s potential exit from generic drugs and disagreements with the Melos over strategy got in the way of a deal, the people said.
Bets similar to those that Pfizer made in Brazil, the world’s third-largest market for the segment, have yielded mixed results, according to industry analysts.
For instance, France’s Sanofi SA has had to record charges related to the booking of excess inventory at Medley Indústria Farmacêutica Ltda, for which it paid $660 million in 2009.
By Tatiana Bautzer and Guillermo Parra-Bernal
Source: Reuters
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
